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The recent increased interest in papers relating to CA 242 in
pancreatic cancer (Haglund et al., 1994; Kawa et al., 1994;
Pasanen et al., 1994) is but one example which highlights the
search for serological tumour markers to facilitate earlier
diagnosis of usually intractable disease. The rationale lies in
the hope that earlier diagnosis will increase curability. Before
looking at the claims of CA 242 and pancreatic cancer in
particular, it is worth perhaps reconsidering what are the
possible roles of serological tumour markers and, more
importantly, which if any of those roles they are likely to
fulfil in clinical practice.
Of the large number of novel putative markers which enter
the literature, and that number has increased by an order of
magnitude with the application (usually empirical) of hybri-
doma technology, very few appear to gain a more than
limited place in clinical use.
In the large majority of cases where markers have a role in
clinical decision making, that role is not diagnostic, but
rather in the follow-up of known patients; either to monitor
the efficacy of ongoing therapy or to give a clinical lead time
to relapse in patients who have undergone previous
treatments. In such follow-up, disease prevalence at any time
will be at least an order of magnitude higher than in the
general population.
There are several possible reasons for the high failure rate
in diagnostic use. Firstly, pilot studies tend to flatter, the
patient cohort tends to be hospitalised and have advanced
bulky disease, in contrast to a control group drawn from the
young and healthy. Studies performed subsequently on a
more appropriate group of patients with earlier stage disease
usually yield less impressive results (Bodansky, 1974).
Secondly, the setting of the 'cut-off value' can lead to prob-
lems; while it is entirely valid to establish empirically a
cut-off that misclassifies the least number ofsubjects in one's
cohort, one cannot then apply statistical tests (e.g. chi-
square) to the same data group. To do so inevitably leads to
an overoptimistic P-value which proves unattainable in
studies using the same cut-off applied to independent data
(Gail & Green, 1976).
A third reason relates to disease prevalence in the group
under study. Consider a study in which an investigator tests
a marker for a cancer which has a prevalence of 100 per
100,000 in the population at large and finds a positive test
result in 99/100 patients. Similarly in 99/100 controls a
negative result is obtained: a test that is 99% sensitive and
99% specific. Owing to this excellent discrimination it is
decided to adopt it for screening for the disease. The results
are a disaster and the test appears to have lost its earlier
power ofdiscrimination. This difference is entirely due to the
change in disease prevalence; the test is still 99% sensitive
and 99% specific but disease prevalence has fallen. In the
first study the prevalence was 50% by design and hence the
positive predictive value (true test positives divided by all test
positives) was 99%. In the screening exercise the prevalence
was 100/100,000 i.e. 0.1%. Therefore, under these circum-
stances, the test would still correctly identify 99/100 with
disease but would also give one false positive per hundred
controls, that is 1,000 of our 100,000 population. Positive
predictive value then becomes 99/(99 + 1,000) or 9%.
It follows therefore that for a serological tumour marker
to have a significant role in screening it must either have a
sensitivity and specificity of 100% or be applied to a popula-
tion in which the disease prevalence is significantly higher
than in the population at large, the best example of the latter
conditions being P-HCG to screen for choriocarcinoma in
women post hydatidiform mole where prevalen is 5-10%
and the positive predictive value of the test approaches 90%,
assuming 99% sensitivity and specificity.
The same hazards of relatively low disease prevalence in
the cohort tested as well as misclassifications as false positive
and false negative (each of which carrie a strong psycho-
logical penalty) arise in the diagnostic use for tumour
markers.
For pancreatic cancer, however, there is recent evidence
(Pasanen et al., 1994) that there may be a clinically useful
role for serological markers in differential diagnosis, whether
used singly or as a panel, in discriminating pancreatic cancer
among symptomatic patients with various GI disorders in
whom there is a high suspicion of malignancy. The relatively
high prevalenc ofpancreatic cancer in such a cohort coupled
with the excellent specificity of monoclonal antibodies
appears to make possible improved differential diagnosis by
judicious use of marker assays.
Many studies have been carried out applying ostensibly
different markers in sequence with the intention either of
identifying a subpopulation who are at significantly higher
risk than the whole population, or of increasing diagnostic
disimination. These studies are proliferating as the number
of putative markers increases. Significant combinations or
panels, however, remain few and far between, perhaps
because of the high degree of congruence between the
markers under consideration; while monoclonal antibodies
are by definition monospecific, it is abundantly clear that the
epitopes to which they bind are not. Furthermore, many
marker antibodies recognise different or partially different
epitopes on the same marker molecule, leading to congruent
rather than complementary results.
Tlhis can be seen in pancreatic cancer studies. CA 242 is
thought to be related to both CA 19-9 and CA 50, although
the detminant is as yet not completely defined. In their
report Haglund et al. (1994) show that CA 242 and CA 19-9
are virtually identical in terms of discinminating pancreatic
cancer. Their point that the former yields higher specificity is
correctly attenuated by their drawing attention to the fact
that this depends on the cut-offs chosen for the tests. To take
their overall data, CA 19-9 is slightly more accurate
[(TP + TN)/(TP + FP + TN + FN)] than CA 242 (82.1% vs
80.7%) and the better specificity of CA 242 (91% vs 81%) is
offset by the sensitivity being lower (74% vs 82.7). These
figures could be changed simply by altering the chosen cut-off
for the assays.
This brings us to another question. Moving the cut-off to
increase specificity inevitably lowers the sensitivity; which of
these two parameters is more useful? There is no simple
answer. As neither parameter is prevalence dependent, both
have their limitations, however in a low-prevalenc situation
it can be demonstrated mathematically that specificity is the
preferred option if we assume a false-negative result and a
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false- tive result to be equally damaing (Roulston, 1990).
The parameters of most clinical use, in that they take
prevalnee into account, are the predictive values. According
to the data of Haglund et al. (1994) the positive predictive
value for CA 242 in this study is 93%, which is high, and
explained by the prevalence of disease in their cohort being
61.5%. CA 19-9 scores 82.6%. Conversely, the negative
predictive values are 69% for CA 242 and 81% for CA 19-9.
The overall performance of a test at various cut-offs is
most readily displayed by a receiver operating characteistic
(ROC) curve in which sensitivity (i.e. the ability to obtain
true positives) is plotted as a function of 1- specificity (i.e.
the faLse-positive rate). A random test (e.g. coin ffip) would
give a straight line passing through the origin at 45-. The
better the test, the greater the area under the curve
(perfect = 1; coin ffip = 0.5). To analyse and assess markers
at single cut-offs is both to lose valuable information and to
mak-e comparisons between different studies extremely
difficult. Similarly, fastidious recording of the details of the
population under study is vital if independent studies are to
be compared (Van der Schouw et al., 1993).
The data of Haglund et al. (1994) (Figures 2-4) indicate
no significant difference between CA 242 and CA 19-9 but
show that CA 242 is significntly better than CA 50 and
CEA, confing previous studies.
In conclusion, the importance of tumour markers stands
upon their ability to provide the clinician with reliable data;
this in turn depends largely upon the disease prevaklnce.
Therefore any studies which seek to define high-risk (i.e.
high-prevalenc) groups, whether by genetic or epidemio-
logical means, should add significantly to the applicability of
tumour markers. Without such breakthroughs it is likely that
tumour markers will in general remain tools for monitoring
and prognosticating rather than for diagnosing or screening.
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